News | September 26, 2023
Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
Subscribe To Our Newsletter & Stay Updated
